^
    No biomarker
    Thymic Carcinoma
    lenvatinib
    Sensitive: A1 - Approval
    No biomarker
    Thymic Carcinoma
    GEM-CAP
    Sensitive: A2 - Guideline
    No biomarker
    Thymic Carcinoma
    LV5FU2
    Sensitive: A2 - Guideline
    No biomarker
    Thymoma
    GEM-CAP
    Sensitive: A2 - Guideline
    No biomarker
    Thymoma
    LV5FU2
    Sensitive: A2 - Guideline
    No biomarker
    Thymic Carcinoma
    CaT
    Sensitive: A2 - Guideline
    No biomarker
    Thymoma
    CaT
    Sensitive: A2 - Guideline
    KIT mutation
    Thymic Carcinoma
    sunitinib
    Sensitive: A2 - Guideline
    No biomarker
    Thymoma
    VIP
    Sensitive: A2 - Guideline
    No biomarker
    Thymic Carcinoma
    VIP
    Sensitive: A2 - Guideline
    No biomarker
    Thymoma
    CAP
    Sensitive: A2 - Guideline
    No biomarker
    Thymoma
    etoposide IV
    Sensitive: A2 - Guideline
    No biomarker
    Thymoma
    ifosfamide
    Sensitive: A2 - Guideline
    No biomarker
    Thymic Carcinoma
    EP
    Sensitive: A2 - Guideline
    No biomarker
    Thymic Carcinoma
    ADOC
    Sensitive: A2 - Guideline
    No biomarker
    Thymic Carcinoma
    CAP + prednisone
    Sensitive: A2 - Guideline
    No biomarker
    Thymic Carcinoma
    CAP
    Sensitive: A2 - Guideline
    No biomarker
    Thymoma
    CAP + prednisone
    Sensitive: A2 - Guideline
    No biomarker
    Thymoma
    ADOC
    Sensitive: A2 - Guideline
    No biomarker
    Thymoma
    EP
    Sensitive: A2 - Guideline
    No biomarker
    Thymic Carcinoma
    carboplatin
    Sensitive: A2 - Guideline
    No biomarker
    Thymic Carcinoma
    paclitaxel
    Sensitive: A2 - Guideline
    No biomarker
    Thymoma
    carboplatin
    Sensitive: A2 - Guideline
    No biomarker
    Thymoma
    pembrolizumab
    Resistant: A2 - Guideline
    No biomarker
    Thymic Carcinoma
    ifosfamide
    Sensitive: A2 - Guideline
    No biomarker
    Thymic Carcinoma
    etoposide oral
    Sensitive: A2 - Guideline
    No biomarker
    Thymic Carcinoma
    pembrolizumab
    Sensitive: A2 - Guideline
    No biomarker
    Thymic Carcinoma
    gemcitabine
    Sensitive: A2 - Guideline
    No biomarker
    Thymic Carcinoma
    prednisone + octreotide
    Sensitive: A2 - Guideline
    No biomarker
    Thymic Carcinoma
    octreotide
    Sensitive: A2 - Guideline
    No biomarker
    Thymic Carcinoma
    everolimus
    Sensitive: A2 - Guideline
    No biomarker
    Thymic Carcinoma
    pemetrexed
    Sensitive: A2 - Guideline
    No biomarker
    Thymoma
    gemcitabine
    Sensitive: A2 - Guideline
    No biomarker
    Thymoma
    paclitaxel
    Sensitive: A2 - Guideline
    No biomarker
    Thymoma
    pemetrexed
    Sensitive: A2 - Guideline
    No biomarker
    Thymoma
    prednisone + octreotide
    Sensitive: A2 - Guideline
    No biomarker
    Thymoma
    octreotide
    Sensitive: A2 - Guideline
    No biomarker
    Thymoma
    everolimus
    Sensitive: A2 - Guideline
    EIF4EBP1 expression
    Thymic Carcinoma
    everolimus
    Resistant: C3 – Early Trials
    HER-2 positive
    Thymic Carcinoma
    pyrotinib
    Sensitive: C3 – Early Trials
    HER-2 mutation
    Thymic Carcinoma
    pyrotinib
    Sensitive: C3 – Early Trials
    IGF1R expression
    Thymoma
    everolimus
    Resistant: C3 – Early Trials
    IGF1R expression
    Thymic Carcinoma
    everolimus
    Resistant: C3 – Early Trials
    EIF4EBP1 expression
    Thymoma
    everolimus
    Resistant: C3 – Early Trials
    KIT D820Y
    Thymic Carcinoma
    sorafenib
    Sensitive: C4 – Case Studies
    PD-L1 overexpression
    Thymic Carcinoma
    pembrolizumab
    Sensitive: C4 – Case Studies
    PD-L1 overexpression
    Thymic Carcinoma
    pembrolizumab
    Resistant: C4 – Case Studies
    PD-L1 overexpression
    Thymoma
    pembrolizumab
    Sensitive: C4 – Case Studies
    EGFR exon 20 insertion
    Thymic Carcinoma
    anlotinib
    Sensitive: C4 – Case Studies
    EGFR exon 19 deletion
    Thymic Carcinoma
    icotinib
    Sensitive: C4 – Case Studies
    MSLN expression
    Thymic Carcinoma
    BAY 94-9343
    Sensitive: D – Preclinical